Biotech Values

[Biowatch]

The only “righting” the ship needs is with respect to Daxxify pricing, which is not rocket science.

As in, lower the price further to increase market share, or raise it to cash in on its superior performance?

Yes, patience is a virtue, but as jbog mentioned, the market isn’t happy.

The latest short interest I saw (September 29) was even higher than before. At some point, the shorts should cover.